Compare Cytokinetics Inc (CYTK) vs General Motors Company (GM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs General Motors Company — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while General Motors Company trades at $82.55 (market cap $72.17B). The key difference: General Motors Company is far larger — about 8.4× Cytokinetics Inc's market cap, and General Motors Company pays a 0.88% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and General Motors Company for 83 Days on average.
| CYTK | GM | |
|---|---|---|
Market Cap | $8.62B | $72.17B |
Volume | 2,594,626 | 4,900,304 |
Sector | Health | Consumer Cyclical |
52-Week High | $87.26 | $90.30 |
52-Week Low | $54.76 | $55.35 |
Typical Hold Time | 19 Days | 83 Days |
Enterprise Value | $8.72B | $175.15B |
Dividend Yield | — | 0.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
General Motors (GM) trades at $80.99, down 1.24% amid broader auto sector weakness. The stock shows mixed signals with bearish technical indicators but strong analyst support (66.7% buy rating) and a $102.08 consensus price target. Recent Q3 2026 sales declined 5.5% due to EV weakness and discontinued models, though the company has beaten earnings estimates for three consecutive quarters. GM benefits from regulatory savings of $20.4B through 2031 from eased fuel economy rules.
GM faces near-term headwinds from declining vehicle sales and competitive pressure from Asian automakers, but maintains solid cash flow and attractive valuation metrics (P/S 0.42). The stock offers 26% upside to analyst targets, though profitability compression and market share losses present ongoing challenges for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →
